Drug intelligence / Profile preview

CLD-202

Development stage: Unknown
Lead developer: Calidi Biotherapeutics
Modality: Cell Therapies, Oncolytic Viruses → Oncolytic Therapeutics
Administration: Intravenous, Intratumoral

Overview

CLD-202 is an investigational, cell-based oncolytic virotherapy developed by Calidi Biotherapeutics for the treatment of metastatic solid tumors. It is part of the "SuperNova" platform and utilizes a systemic delivery approach to target both local and distant tumor sites. The therapy consists of stem cells loaded with an oncolytic virus, designed to deliver the virus directly to tumor tissue, where it can selectively infect and lyse cancer cells while stimulating antitumor immune responses. Preclinical studies have demonstrated its ability to inhibit tumor growth in multiple solid tumor models. As of June 2025, CLD-202 remains in preclinical (discovery) development[1][2][3].

Other names: SuperNova

Beyond the preview

Go deeper on CLD-202.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CLD-202.

Explore the full profile